Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk
Conditions
Interventions
Efpeglenatide (SAR439977)
Placebo
Locations
353
United States
Investigational Site Number 8400032
Sheffield, Alabama, United States
Investigational Site Number 8400014
Gilbert, Arizona, United States
Investigational Site Number 8400012
Surprise, Arizona, United States
Investigational Site Number 8400046
Tucson, Arizona, United States
Investigational Site Number 8400022
Beverly Hills, California, United States
Investigational Site Number 8400065
Concord, California, United States
Start Date
April 27, 2018
Primary Completion Date
December 10, 2020
Completion Date
December 10, 2020
Last Updated
October 15, 2021
NCT07232537
NCT06278207
NCT07051005
NCT06887049
NCT07433062
NCT04943861
Lead Sponsor
Sanofi
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions